Idea
AI-assisted clinical data cleaning platform that accelerates trial data review and reduces errors for pharmaceutical companies and CROs
Research Paper
Core Innovation
This paper introduces Octozi, an AI-assisted platform that integrates large language models with domain-specific heuristics to significantly improve clinical data cleaning speed and accuracy. Unlike traditional manual methods, it reduces error rates and false positive queries substantially while maintaining compliance. The approach is effective regardless of reviewer experience, enabling broad adoption.
Market Size (TAM)
$2–10B TAM, $1–2B SAM; assumption: clinical trial data management is a critical and growing segment in pharmaceutical R&D with increasing AI adoption.
Potential Customers & Pain Points
- Pharmaceutical Companies Facing Slow Clinical Data Cleaning
- Contract Research Organizations Needing Efficient Data Review
- Clinical Data Managers Struggling with High Error Rates
Business Model
Subscription-based SaaS platform with tiered pricing based on data volume and user seats; enterprise licensing for large pharma and CROs.
Competitive Landscape
- Medidata
- Oracle Health Sciences
- Veeva Systems
Implementation Challenges
- Regulatory Compliance and Validation
- Integration with Existing Clinical Data Systems
- User Trust and Adoption of AI Recommendations
Validation Strategy
- Pilot deployment with select pharmaceutical companies
- Measure throughput and error reduction against baseline
- Collect user feedback to refine AI heuristics and interface
Research Paper Overview
Leveraging AI to Accelerate Clinical Data Cleaning: A Comparative Study of AI-Assisted vs. Traditional Methods
Summary
Clinical trial data cleaning is a bottleneck in drug development due to manual review limits. Octozi, an AI-assisted platform combining large language models and domain heuristics, boosts data cleaning throughput by 6.03x and reduces errors from 54.67% to 8.48%, cutting false positive queries 15.48-fold. Improvements are consistent across reviewer experience, suggesting broad applicability and potential to accelerate drug development while maintaining compliance.